Atea Pharmaceuticals (AVIR) has projected peak annual U.S. net revenue potential in excess of $700 million, centering its strategy on a mid-2028 launch for its hepatitis C (HCV) treatment. This outlook follows significant progress highlighted during the company’s Q2 2026 management view.
A key driver for this revenue forecast is the positive top-line results from the C-BEYOND Phase III trial. This pivotal study evaluated the combination of bemnifosbuvir for the treatment of hepatitis C in North America. The company’s Founder, Chairman, CEO & President stated, ‘The positive top line results from C-BEYOND, our Phase III trial evaluating the combination of bemnifosbuvir for the treatment of hepatitis C in North America represents a significant milestone for Atea.’
The successful Phase III trial positions Atea Pharmaceuticals to advance its bemnifosbuvir combination therapy towards regulatory approval, targeting the substantial U.S. market for HCV treatment. The mid-2028 launch timeline indicates the company’s strategic focus on bringing this therapy to patients within the next few years.
This development underscores Atea’s commitment to addressing unmet needs in hepatitis C treatment and provides a clear financial trajectory for the company’s lead asset in the coming years.
